Edition:
United States

Profile: Celldex Therapeutics Inc (CLDX.O)

CLDX.O on Nasdaq

2.92USD
20 Oct 2017
Change (% chg)

$-0.05 (-1.68%)
Prev Close
$2.97
Open
$3.00
Day's High
$3.00
Day's Low
$2.88
Volume
715,532
Avg. Vol
1,430,967
52-wk High
$5.02
52-wk Low
$2.20

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Company Address

Celldex Therapeutics Inc

53 Frontage Rd Ste 220
HAMPTON   NJ   08827-4034
P: +1908.2007500
F: +1908.4541911

Company Web Links